The Triple Agonist

What If We Didn't Stop at Two Receptors?

Retatrutide is what happens when scientists ask: what if we didn't stop at two receptors? Semaglutide hit one. Tirzepatide hit two. Retatrutide hits three — GLP-1, GIP, and glucagon — and the results are something the weight loss field had never seen before: 24.2% weight loss with no plateau at 48 weeks.

View Retatrutide Full GLP Comparison

24.2%

Average weight loss (Phase II, 48 weeks)

Receptors activated simultaneously

Weight loss plateau at 48 weeks

58 lbs

Average loss for 240lb person

The GLP Evolution: One Receptor at a Time

Each generation of GLP-based therapy added a receptor and dramatically expanded results. Retatrutide is the logical third step — and each addition has delivered non-linear gains.

Semaglutide

(2017)GLP-1~15% loss

First GLP-1 agonist to demonstrate significant weight loss in non-diabetics. Changed how medicine thought about obesity as a treatable condition.

Tirzepatide

(2022)GLP-1 + GIP~22.5% loss

Adding GIP receptor agonism produced synergistic fat loss that exceeded predictions. The SURPASS-2 trial showed superiority over semaglutide at every dose tested.

Retatrutide

(2024–2026)GLP-1 + GIP + Glucagon~24% loss

The glucagon receptor is the metabolic rate dial. Adding glucagon agonism raises basal energy expenditure — you burn more calories at rest. The trial showed no plateau at 48 weeks, which had never been seen before.

Explore the Triple Receptor Mechanism

Click each receptor to understand what it contributes to the 24% weight loss result.

Retatrutide: Triple Receptor Mechanism Explorer

Retatrutide activates three receptors simultaneously. Select each to understand its unique contribution to the 24% weight loss result.

GLP-1 Receptor — What It Does

Appetite Suppression

Acts on hypothalamic GLP-1 receptors to reduce hunger signals and extend satiety between meals.

Gastric Emptying

Slows gastric emptying, extending the satiety signal from meals and improving post-meal glucose control.

Insulin Secretion

Glucose-dependent insulin stimulation — only triggers insulin release when blood glucose is elevated, minimizing hypoglycemia risk.

Clinical Context

Shared mechanism with semaglutide. Contributes ~15% weight loss on its own.

15%

Semaglutide
(GLP-1 only)

→

22.5%

Tirzepatide
(GLP-1 + GIP)

→

24.2%

Retatrutide
(GLP-1 + GIP + Glucagon)

Phase II data. Phase III ongoing. For research and educational purposes only.

Why the Glucagon Receptor Changes Everything

Adding GIP to GLP-1 pushed weight loss from 15% to 22.5%. Adding glucagon pushed it to 24.2% — but the more important finding was no plateau. Here's what the glucagon receptor actually does in the retatrutide context.

🔥

Hepatic Fat Oxidation

Glucagon receptor activation drives the liver to oxidize fat directly. This is why glucagon was historically dismissed — it raises blood glucose by driving hepatic glycogenolysis. But in the context of GLP-1 coactivation, the blood glucose elevation is suppressed while the fat oxidation effect remains, giving you all the metabolic upside without the hyperglycemia.

⚡

Basal Metabolic Rate Elevation

This is the key differentiator from tirzepatide. Glucagon receptor activation raises resting energy expenditure — your BMR goes up even without exercise. In the Phase II trial, this effect appeared to compound over time rather than plateau, explaining why weight loss continued straight through week 48.

🌡️

Thermogenesis in Brown Fat

Glucagon receptors on brown adipose tissue (BAT) drive thermogenesis — heat generation from fat burning. Brown fat activation is one of the most sought-after mechanisms in metabolic medicine. Retatrutide appears to activate this pathway in ways that semaglutide and tirzepatide do not.

Triple Agonist Research Peptide

Retatrutide 10mg

Retatrutide is available as a research peptide at 10mg per vial. At typical weekly doses of 6–10mg, a 10mg vial provides 1–2 weeks of supply depending on your protocol stage. The slow escalation protocol is critical — beginning at 1–2mg/week and increasing gradually to minimize GI side effects.

10mg per vial Triple receptor agonist Weekly SC injection Phase II validated dose range

View Retatrutide 10mg

Phase II Trial Data at a Glance

Duration	48 weeks
Participants	338 adults (non-diabetic, BMI ≥27)
Primary endpoint	Percent change in body weight
Max dose tested	12mg weekly SC
Average weight loss at max dose	24.2%
Plateau observed?	No — trajectory still downward at week 48
Phase III status	Ongoing (TRIUMPH program)

Source: Jastreboff et al., NEJM 2023. Phase II dose-ranging trial of retatrutide in adults with obesity.

GLP-1 Single Agonist

Semaglutide 6mg

The original GLP-1 agonist and still the most studied. For those starting a GLP-1 protocol, semaglutide provides proven results with the most established safety record. Once you've experienced the GLP-1 mechanism, upgrading to tirzepatide or retatrutide for greater efficacy is a logical next step.

View Semaglutide 6mg

Semaglutide vs Tirzepatide vs Retatrutide

Metric	Semaglutide	Tirzepatide	Retatrutide
Mechanism	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Avg weight loss	~15%	~22.5%	~24.2%
Plateau	Yes (~20 weeks)	Yes (~24 weeks)	Not observed at 48w
BMR elevation	Minimal	Moderate	Significant
Liver fat reduction	Good	Better	Best
Data maturity	5+ years	3 years	Phase II complete
Approval status	FDA approved	FDA approved	Phase III ongoing

Frequently Asked Questions

How is retatrutide different from tirzepatide?+

The key addition is the glucagon receptor. Tirzepatide hits GLP-1 and GIP — and that gets you to ~22.5% weight loss. Retatrutide adds glucagon receptor agonism on top, which raises basal metabolic rate directly. You're not just eating less (GLP-1) and managing fat storage differently (GIP) — you're also running hotter metabolically (glucagon). In the Phase II trial, this translated to an additional ~2% weight loss beyond tirzepatide, with the crucial observation that weight loss hadn't plateaued at 48 weeks.

Why does the glucagon receptor raise metabolic rate?+

Glucagon is classically thought of as a glucose-raising hormone — the opposite of insulin. But glucagon also directly stimulates fatty acid oxidation in the liver and activates thermogenic processes in brown adipose tissue. When given alongside GLP-1 agonism, the glucose-raising effect is blunted (GLP-1 also triggers insulin and suppresses glucagon), but the fat oxidation and thermogenic effects remain. The result is elevated resting energy expenditure — you burn more calories just existing.

Is retatrutide approved by the FDA?+

Not yet, as of early 2026. Phase II data was published in 2023, and the TRIUMPH Phase III program is ongoing. Eli Lilly has indicated a regulatory submission timeline, but approval is likely 2027–2028 at the earliest if trials succeed. Retatrutide is currently available as a research peptide through suppliers serving the research community.

What are the side effects of retatrutide?+

The Phase II trial reported similar side effect profiles to tirzepatide and semaglutide — primarily GI: nausea, vomiting, diarrhea, and constipation. The glucagon component can cause additional nausea at higher doses. Importantly, the trial used a slow dose escalation protocol, which significantly reduced discontinuation rates. The side effect burden appears manageable with proper titration — similar to tirzepatide.

How do I dose retatrutide as a research peptide?+

The Phase II trial escalated from 1mg/week to a maximum of 12mg/week over 24 weeks. Research users typically follow a similar slow escalation: starting at 0.5–1mg/week, increasing by 1mg every 4 weeks until the target dose or side effect threshold is reached. Most research protocols land between 6–10mg/week as the maintenance target. Slower escalation is always better — GI adaptation takes time.

Will retatrutide outperform tirzepatide for everyone?+

Not necessarily. The average improvement in the trial was ~2% additional weight loss. But individual responses to the glucagon component vary — some users will see dramatically better results with the metabolic rate elevation, while others may find the added GI burden isn't worth the marginal gain over tirzepatide. The "no plateau" finding at 48 weeks is the most compelling reason to consider retatrutide for very long-term protocols where tirzepatide's plateau may otherwise stop progress.

What's the Phase III TRIUMPH trial testing?+

The TRIUMPH program includes multiple Phase III trials testing retatrutide in various populations — adults with obesity without diabetes, adults with type 2 diabetes, and cardiovascular outcomes. These trials will determine whether the Phase II results hold up at scale, what the long-term safety profile looks like, and whether the FDA will approve it for weight management. Results from the larger trials are expected between 2025 and 2027.

The Most Powerful Weight Loss Peptide Available

Retatrutide is the frontier of GLP-based fat loss research. Available now as a research peptide for those who want results that even tirzepatide can't fully deliver.

Shop Retatrutide Start With Tirzepatide